Company type
Biopharma company focused on identifying, developing, and commercialising novel treatments in orphan indications with significant unmet medical needs.Overview
Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
Funding rounds
Debt EUR 92,000,000
( )
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Athyrium Capital Management LP | Initial investment. Led the round. |
Debt EUR 68,000,000
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Kreos Capital | Provider of flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors. | EUR 68,000,000 Initial investment. Led the round. Exited. (Repayment of preference shares/ loans or mezzanine) |
Investment activity status
Active investor